
    
      An opened label trial designed to evaluate CG0070 and DDM in combination with Pembrolizumab
      in patients with NMIBC who have failed prior BCG therapy.

      The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1
      papillary disease will be enrolled.

      BCG failure is defined as persistent or recurrent disease within 12 months of completion of
      adequate BCG therapy.
    
  